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study question: What do scientists in the field of preimplantation genetic diagnosis (PGD) and preimplantation genetic screening
(PGS) consider to be the future direction of comprehensive embryo testing?
summary answer: Although there are many biological and technical limitations, as well as uncertainties regarding the meaning of
genetic variation, comprehensive embryo testing will impact the IVF/PGD practice and a timely ethical reflection is needed.
what is known already: Comprehensive testing using microarrays is currently being introduced in the context of PGD and PGS,
and it is to be expected that whole-genome sequencing will also follow. Current ethical and empirical sociological research on embryo testing
focuses on PGD as it is practiced now. However, empirical research and systematic reflection regarding the impact of comprehensive tech-
niques for embryo testing is missing.
study design, size and duration: In order to understand the potential of this technology and to be able to adequately
foresee its implications, we held an expert panel with seven pioneers in PGD.
participants/materials, setting, methods: We conducted an expert panel in October 2011 with seven PGD pioneers
from Belgium, The Netherlands, Germany and the UK.
main results and the role of chance: Participants expected the use of comprehensive techniques in the context of PGD.
However, the introduction of these techniques in embryo testing requires timely ethical reflection as it involves a shift from choosing an
embryo without a particular genetic disease (i.e. PGD) or most likely to result in a successful pregnancy (i.e. PGS) to choosing the best
embryo based on a much wider set of criteria. Such ethical reflection should take account of current technical and biological limitations
and also of current uncertainties with regard to the meaning of genetic variance. However, ethicists should also not be afraid to look
into the future. There was a general agreement that embryo testing will be increasingly preceded by comprehensive preconception screening,
thus enabling smart combinations of genetic testing.
limitations, reasons for caution: The group was composed of seven participants from four Western Europe countries. As
willingness to participate in this study may be connected with expectations regarding the pace and direction of future developments, selection
bias cannot be excluded.
wider implications of the findings: The introduction of comprehensive screening techniques in embryo testing calls for
further ethical reflection that is grounded in empirical work. Specifically, there is a need for studies querying the opinions of infertile
couples undergoing IVF/PGS regarding the desirability of embryo screening beyond aneuploidy.
study funding/competing interest(s): This research was supported by the CSG, Centre for Society and Life Sciences
(project number: 70.1.074). The authors declare no conflict of interest.
& The Author 2013. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
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Introduction
Genetic testing of biopsied cells from in vitro embryos is currently done
for two different reasons in two different contexts. The first one is
when prospective parents have an increased (recurrence) risk of con-
ceiving a child with a genetic (in most cases Mendelian or chromosom-
al) disorder. This is called preimplantation genetic diagnosis (PGD). In
many cases, this regards fertile couples who want to avoid transmitting
the genetic condition, but prefer not (again) to try the route of pre-
natal diagnosis and a possible termination of pregnancy. As long as
PGD is used for highly penetrant mutations and serious disorders, it
is a relatively uncontroversial option, although the status of the preim-
plantation embryo remains a topic of controversy. Preimplantation
genetic screening (PGS), secondly, is the routine testing of embryos
resulting from IVF treatment. Currently, such screening is limited to
testing for aneuploidy. A set of selected (or all) chromosomes are
counted, to check for monosomy (the lack of one chromosome of
the normal complement), trisomy, tetrasomy or pentasomy (the pres-
ence of three, four or five copies of a given chromosome), with the
assumption that transferring an euploid embryo, which has only two
copies of a given chromosome, will enhance the chance of a successful
pregnancy (Fragouli and Wells, 2012). Worldwide, many centres have
started offering PGS for patients with advanced maternal age, recur-
rent implantation failure or recurrent pregnancy loss, as those
groups would theoretically benefit most from such screening.
However, the American Society of Reproductive Medicine (ASRM),
the British Fertility Society and the European Society of Human Repro-
duction and Embryology (ESHRE) have concluded that PGS using
fluorescent in situ hybridization (FISH) does not, at the moment,
improve the live birth rates in those patient groups (Mastenbroek
et al., 2007; Anderson and Pickering, 2008; Harper and Sengupta,
2011). One factor responsible for this lack of success is the phenom-
enon of mosaicism: the fact that the cell(s) taken from the embryo
may not be representative of the rest of the embryo, especially
when the embryo biopsy is done at the cleavage stage (Day 3). As
a result, a fraction of embryos that would be able to develop into
healthy fetuses are excluded from transfer. A second assumption is
that FISH, which was thus far the main method used, looks at less
than half of the chromosomes at the same time, thereby possibly
missing important information from the other chromosomes. More-
over, the presence, absence or the interpretation of FISH signals is
not always straightforward and may lead to misdiagnosis. Thirdly,
embryo biopsy, especially at the cleavage stage, may negatively influ-
ence an embryo’s viability. Microarrays, such as array-CGH (compara-
tive genomic hybridization) and SNP array, allow for the screening of
all chromosomes simultaneously, removing the second limitation.
They also allow for the detection of submicroscopic chromosomal ab-
normalities such as large insertions or deletions. This technique also
seems more reliable and may result in less misdiagnosis. If the polar
body (Day 1) or trophectoderm cells (Day 5) are used, this is
deemed to be less invasive for the embryo. Some studies have
shown a positive effect on the chance of a successful pregnancy
with the use of microarray technology for such ‘comprehensive’
chromosome screening (Forman et al., 2012; Scott et al., 2012;
Treff et al., 2012; Yang et al., 2012). More randomized controlled
trials are underway to test the efficiency of PGS by means of micro-
array analysis at the zygote stage by looking at polar bodies (Harper
et al., 2008, 2010; Geraedts et al., 2010). Besides the already available
microarray technology, it is expected that whole-genome sequencing
of single cells will eventually be clinically applicable in the context of
embryo testing as well (Baslan et al., 2012).
A considerable number of empirical sociological and psychological
studies have been published reporting qualitative and quantitative
data about traditional PGD (Miedzybrodzka et al., 1993; Palomba
et al., 1994; Snowdon and Green, 1997; Lavery et al., 2002; Roberts
and Franklin, 2004; Zeiler, 2004; Ehrich et al., 2006, 2007; Williams
et al., 2007; Ehrich and Williams, 2010). These studies typically aim
to describe the dynamics of PGD as it is currently practiced, targeting
specific diseases, and to provide insight into the experiences of practi-
tioners and patients.
Preimplantation genetic testing has also been widely discussed in the
ethics literature. Issues covered include the status of the human
embryo, the principle of respect for reproductive autonomy, the
impact of reproductive testing and selection on the rights of the dis-
abled in society, a supposed duty to select the best embryo and
fears regarding a slippery slope toward creating ‘designer children’
(Robertson, 2003; Savulescu and Kahane, 2009; Wilkinson, 2010).
We are now on the verge of the era of comprehensive genetic tests,
such as microarray analysis and whole-genome sequencing. This may
revolutionize our knowledge of embryos’ genotypes and substantially
increase the options for informed selection. Moreover, progress on
the genetic level has gone hand in hand with progress in IVF-related
techniques such as vitrification and in vitro maturation of oocytes
(Kuwayama et al., 2005; Zheng et al., 2005; Wang et al., 2011).
Embryo freezing may remove current limitations on time schedules
needed for diagnostic tests, whereas in vitro maturation may increase
the number of oocytes and, as a consequence, embryos to select
from. The implications of this evolution call for a timely ethical reflec-
tion, which should be embedded in scientific reality but not afraid to
assess potential future directions as well (De Wert, 2009). To under-
stand the dynamics of comprehensive embryo testing and to assess
the scope and content of ethical reflection on this topic, we queried
the opinions of PGD pioneers in an expert panel.
Materials and Methods
In order to arrive at an exploration of possible ethical questions
informed by an inside assessment of the pace and direction of
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technological developments in the field of genetic testing and artificial
reproductive technologies (ART), we invited a group of pioneers of
embryo testing for an expert panel at Maastricht University. The
meeting was held in the context of a campus course on comprehen-
sive embryo testing organized by the special Interest Groups ‘Repro-
ductive Genetics’ and ‘Ethics & Law’ of ESHRE. Participants in the
expert panel were seven scientific experts with many years of experi-
ence in PGD. [The participants were Edith Coonen (Maastricht Uni-
versity), Christine De Die-Smulders (Maastricht University), Joep
Geraedts (Maastricht University), Alan Handyside (The Bridge Fertility
Centre, London), Joyce Harper (University College London), Udo
Koehler (Medizinisch Genetisches Zentrum, Munich), Karen Sermon
(Free University of Brussels) and Evelyne Vanneste (Catholic Univer-
sity of Louvain).]
A topic guide was developed by K.H., W.D. and G.W., describing
four different possibilities of the future direction of embryo testing.
Participants were asked to reflect on these possibilities and give
their technical and ethical opinions. First, we presented the possibility
that aneuploidy screening was added to PGD for specific disorders.
Secondly, we queried the participants about the possibility to test
for many Mendelian conditions simultaneously, both in the context
of PGD and PGS. Thirdly, the possibility of also screening embryos
for complex disorders was discussed. To conclude, the more futuristic
scenario of testing for non-health-related traits was presented to the
participants. G.W. and W.D. were moderators; K.H. was an observer.
The meeting was taped and later transcribed and analyzed by K.H.,
G.W., J.G. and W.D., using NVIVO9 to extract the main themes. In
this report, we shall describe the result of this analysis and the conse-
quences for the ethical debate on the issue. In order to avoid easy rec-
ognizability of individual contributions, all participants are referred to
as ‘she’ and ‘her’. Quotes are included quasi-literally, but we have
inserted clarifications in square brackets where necessary and have
adapted some words to increase understandability.
Results and Discussion
Possibilities and limitations of embryo testing
Increasing the resolution of genetic embryo testing is a recent devel-
opment, and therefore still subject to uncertainties regarding its
future direction, for example, regarding the applicability of whole-
genome sequencing. At present, there are many aspects that limit
the development of its full potential. Our participants mentioned
three types of limitations: technical limitations related to the state of
the art of the technology itself, biological limitations and limitations
related to the current lack of knowledge regarding the meaning of
genetic variance. Technical limitations were related to current
testing techniques, specifically the difficulty of single-cell whole-
genome sequencing and the amplification of DNA. Also, the limited
number of embryos resulting from an IVF cycle, which is a biological
limitation, severely limits the range of possible applications of
embryo testing today. However, participants were also convinced
that such technical limitations will most likely be overcome in the
not too distant future.
. . . , but before that nobody could foresee that PCR would be that suc-
cessful for a number of applications.
In this quote, the participant asserts her belief that even technical lim-
itations that seemed insurmountable in the past have been overcome
and, consequently, the same will be true for current and future tech-
nical limitations.
Apart from technical, and surmountable, limitations, participants
also stressed the importance of acknowledging biological limitations,
which may be more difficult, if not impossible, to overcome, as is
clear from the following quote:
But who knows in the future, yes we may have better whole genome amp-
lification but we are still limited by the biology.
One such limitation participants repeatedly quoted is the fact that in a
woman of advanced maternal age, the number of oocytes without
chromosomal abnormalities is limited if not zero. Another biological
limitation is that embryo selection is limited by the fact that, apart
from de novo mutations, all genetic variation is inherited from either
parent. These limitations may effectively tighten the scope of selection,
or make the technique unreliable altogether.
However, there was firm belief among some participants that com-
prehensive screening of embryos will ultimately be possible and will be
practiced, and that this development has already taken a start now:
. . . as far as I am concerned, GATTACA is here. We could do this at a
basic level now, we could do a genome scan of the parents and then
decide what we want to do with the embryo. Right now, we are
already doing a genome scan of the embryo and selecting the fittest
embryo.
The participant refers here to the movie GATTACA, a dystopic tale
depicting a future where many people are selected after genetic ana-
lysis and profiling of embryos resulting from ART.
Finally, participants stated that the techniques to detect genetic vari-
ation evolve far more rapidly than knowledge about the interpretation
of genetic variants. They disagreed with the view that the more com-
prehensively embryos are tested, the more transparent they will
become, as is clear from the following quote:
The possibility of fully understanding the embryo are separate from the
possibility of comprehensively screening and testing the embryo on each
level I think.
The term comprehensive is therefore first and foremost applicable to
the technique of screening and sequencing rather than to the actual
interpretation. This may directly lead to the concern that, as long as
knowledge is lagging behind, couples seeking PGS or PGD may be pre-
sented with genetic information of unknown significance and may take
probabilities for certainties. Obviously, this has major implications for
genetic counselling, as is clear from the following quote:
I mean the fact that you generate data that you don’t know how to com-
municate to the couple. . . . Even we ourselves do not understand the data
we are generating. I think that generates ethical dilemmas that we should
discuss.
In this quote, the participant explicitly states that this asymmetry
between the information these techniques yield and the knowledge
available to fully understand the test results raises important ethical
issues that need to be well thought through. It is a call to ground
ethical reflection firmly in realistic dilemmas that are already
foreseeable.
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However, participants also stressed the need for ethicists to look
beyond technical, biological and informational limitations and consider
a future where these limitations are overcome:
But I think ethicists should look forward and should try to foresee future
problems. What if we look at the whole genome and if we look at things
like CNVs [Copy Number Variants] and cancers, cancer genes or high risk
genes for for example high blood pressure or that stuff. That’s I think the
important discussion.
The abundance of information that may be yielded by such compre-
hensive tests, together with the gaps in the current knowledge
about genetic variation and the fact that many genetic mutations
yield probabilistic information, raised questions amongst our partici-
pants about how to communicate this information to the couple
and how to facilitate decision-making. In the study of PGD staff by Wil-
liams et al., it is stated that PGD staff would find it difficult to argue
with couples requesting PGD for genetic risk factors, such as BRCA
mutations, as such couples already have experience with these condi-
tions in their families (Williams et al., 2007). If such information comes
as an add-on to the original clinical question, this experience is absent,
which will potentially complicate decision-making. A further issue in
this regard concerns the challenge of presenting the information on
what choices between embryos have to be made in a way that
would allow meaningful informed consent. Also, the possibility that
each embryo may have a number of genetic abnormalities, either
related to degrees of viability in the womb or to health, be it congeni-
tal or later in life, may lead to the fact that difficult or even impossible
trade-offs will have to be made by the couple or by the professionals
involved (Health Council of the Netherlands, 2010). The ideal stand-
ard of non-directive genetic counseling states that professionals should
provide information and support that enables their clients to make
their own well-informed decisions. This is based on the moral principle
of respect for autonomy. However, authors have questioned whether
such autonomous choice is actually possible or even desirable in the
context of PGD (Williams et al., 2002). Roberts and Franklin have
found in their ethnographic study of PGD that couples are well
aware of the fact that their choices required careful thought and con-
sideration about the implications and issues at stake (Roberts and
Franklin, 2004; Franklin and Roberts, 2006). But the finding that
most, if not all, couples undergoing traditional PGD do in fact make
well-considered decisions cannot automatically be extended to the
context of comprehensive genetic screening in the context of PGS.
Here, there is potentially an explosion of choices and technological
possibilities that couples may believe are necessary to explore or
feel they cannot refuse. How grounded the fear that this may com-
promise their decision-making capacity is can only be answered by
further research into the experiences of couples opting for IVF/PGS.
Broadening the scope: from single defects to
genetic health profiles
The participants regarded ‘testing for a specific disease combined with
screening for chromosomal abnormalities’ as a potentially valuable
add-on to traditional PGD for particular genetic disorders. Such
screening may facilitate the selection of an embryo that is both
without the genetic disorder that was the indication for PGD and
that is likely to implant as it has no serious chromosomal disorder.
Moreover, as comprehensive chromosome screening can reveal
trisomy-21 or other viable chromosomal abnormalities, including sub-
microscopic chromosomal abnormalities, such screening also implies
screening for embryos with serious but viable conditions:
So it is all the way from gross genetic defects that simply affect the embryo
viability through to milder imbalances that give rise to potentially affected
children.
This means that not only do these techniques allow for the selection
of an embryo most likely to lead to a succesful pregnancy, but also to
select against embryos likely to develop into a child with a chromo-
somal defect with multiple congenital anomalies and mental
retardation.
Adding comprehensive chromosome screening to a PGD proced-
ure aimed at avoiding a specific genetic disease may increase the
chance that an embryo is chosen that will likely implant and unaffected
by the condition in question and unrelated chromosomal abnormal-
ities. Ehrich and Williams have presented the idea that the practice
of selecting embryos in the context of traditional PGD, focusing on
single disorders, is subject to a ‘double imperative’: PGD automatically
involves IVF, a practice which is traditionally aimed at producing viable
pregnancies, hopefully leading to the birth of a ‘healthy’ child. In view
of the combined aims of IVF and PGD, therefore, embryos must be
judged viable by embryologists and unaffected by geneticists (Ehrich
and Williams, 2010).
The fact that there is this double imperative in the context of trad-
itional PGD may, we think, explain why adding comprehensive
chromosome screening to PGD seemed logical to our participants,
as this would allow selecting against non-viable embryos and affected
embryos alike. Conversely, if the original aim of PGS is to improve the
chances that IVF will help the couple to have a baby, adding screening
for common genetic mutations to PGS would make it possible for the
professional to help them to have a healthy baby, thus answering to the
same double imperative also when testing is done in the context of
traditional IVF. However, it is relatively straightforward that a couple
opting for PGD has hopes for a successful pregnancy, but an infertile
couple hoping for a successful pregnancy may not automatically desire
genetic testing for a range of conditions, a distinction worth reflecting
on before introducing these tests in the clinic.
It was stated by our participants that the use of higher resolution
techniques such as SNP arrays and eventually whole-genome sequen-
cing allow for ‘testing for a specific disease and other gene defects, in-
cluding copy number variants (CNVs) and chromosomal aberrations
simultaneously’. Participants mentioned the identification of genes
coding for infertility as a first application that may be especially
useful for the group of subfertile patients. One participant saw great
potential and public health gain in the growing knowledge about the
relation between CNVs and mental retardation:
So the same copy number variants are now being associated with mental
retardation and people have argued that every pregnancy should be
screened for CNVs. Because the impact on the health system of avoiding
these genetic causes of mental retardation and so on would be quite
considerable.
Here, she describes how discussions about the increasingly higher
resolution of the technology in prenatal testing are already ongoing,
and that a reflection on testing embryos for CNVs as well is
needed. Also the ‘inclusion of testing for risk factors and complex
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diseases’ was considered by our participants. One of the main draw-
backs with this inclusion they saw is the current lack of knowledge
about the meaning of genetic variation that was discussed in the pre-
vious section. Another drawback is the fact that, if all genes and con-
ditions were to be considered, no unaffected embryos would be left to
transfer:
I think we are here on the edge now, because everyone of us is abnormal.
And if we then screen at a very high level, we cannot choose the normal
embryo, because every embryo will become abnormal. We have to
choose a combination of abnormalities to give to the parents, and [give
back] the most normal.
Indeed, it may no longer be possible to pick an unaffected embryo.
Instead, rather than a ‘healthy’ embryo, the embryo with the best
health profile will be transferred.
So far, broadening the scope of PGD has been studied in the em-
pirical literature in the context of broadening the number of conditions
for which targeted PGD would be indicated. A study by Williams et al.
describes opinions of staff of PGD clinics regarding PGD for late onset
or low penetrance diseases. They found that staff had concerns about
widening the criteria for doing PGD, but also thought it difficult to
argue with couples who had first-hand experience with the condition
in question (Williams et al., 2007). However, if such conditions are
detected as part of comprehensive PGS or PGD, rather than being
the initial reason why the procedure is requested, some of the barriers
may be lifted. Indeed, the discussion about allowing targeted PGD for
additional conditions is partly one about the proportionality of the
procedure. As PGD involves IVF, the benefits of allowing PGD for
less serious, late onset or low penetrance diseases may not weigh
up against the burdens, risks and material or immaterial costs of the
procedure. However, if such information comes for free along with
the information actually sought for, this barrier is already lifted and ex-
pansion of the scope of testing may be more acceptable for some
people.
Broadening the scope: from health-related to
non-health-related characteristics
Evolving genetic knowledge and comprehensive testing techniques
may also lay bare the pathway toward testing for non-medical traits.
This possibility was something some of the participants were
anxious about. In this respect, sex selection was thought to be the
‘first snowflake’ on the route to prospective parents wanting to
select an embryo with many other non-health-related characteristics.
As discussed in the previous section, one participant explicitly men-
tioned the 1997 movie GATTACA, depicting a future society where
most conceptions involve screening embryos and selecting the
embryo with the best potential of developing into a child that will
flourish in society. It was clearly pointed out that the techniques in
that movie are not applied as of yet, but they might be sooner or
later. One participant particularly was convinced that couples would
be interested in this type of selection, should selection based on
such traits become technically possible:
If you look at how some parents force their children to go to music
schools without having a perfect pitch, and to do well in sports and to
have classes after. . . . Everybody wants the perfect child, and there are
very few parents that can accept defaults or flaws in their children. (. . .)
I think many parents will accept the notion—whether that is right or
wrong—, but they will accept the step to going to select traits in their chil-
dren or in the embryos or whatever.
This participant saw the desire to genetically select the ‘best perform-
ing’ child as a logical next step in a society where parents invest heavily
in their children. Interestingly, she mentions the fact that parents often
also force children to perform, be it in sports or in music. Selecting
children with desirable traits is considered analogous to other types
of parental pressure.
The qualitative interview study by Roberts and Franklin describes
how couples undertaking traditional PGD grounded their wish to
undertake PGD in the context of a parental duty to avoid grave suffer-
ing and premature death and clearly resented any association with the
concept of a ‘designer baby’ (Roberts and Franklin, 2004). However,
as genetic knowledge progresses even further, embryos could perhaps
also be selected for non-medical characteristics, such as intelligence.
Although knowledge about the genetics of such complex traits is still
limited today, studies have already demonstrated the genetic basis
of traits such as absolute pitch and height (Weedon et al., 2007;
Theusch et al., 2009; Lango Allen et al., 2010), traits which may be
of potential interest to future parents. This would ultimately mean
that one could not only select for a healthy child or a child with the
best health prospects later in life, but for what the prospective
parents would regard as the ‘best child’, all things considered. Some
of our participants indeed thought that, should information about
non-health-related traits come ‘for free’ as part of a comprehensive
test, couples would be interested in including this into the selection
process. On the one hand, one participant linked this to the idea of
parents putting pressure on their children to perform, which is a far
cry from the parental duty to avoid grave suffering in offspring
described by Roberts and Franklin. On the other hand, some scholars
have argued that selection for non-health-related traits that may be
beneficial to the future child should be considered a parental duty,
rather than an expression of a parental whim (Savulescu and
Kahane, 2009).
Preconception carrier screening and embryo
screening for all
Confronted with the scenario of testing for a broader range of genetic
disorders, participants argued that to avoid technical problems related
to single-cell comprehensive embryo testing, it would be more advis-
able to preconceptionally test the parents first. If such a preconception
test reveals that the couple is at high genetic risk, a targeted test can
thereafter be used for the embryo:
So I think the one privilege that an infertile couple has is that they have the
opportunity—they haven’t had an affected child, they haven’t had a
child—, so they can actually ask the question am I carrying anything dele-
terious? And in particularly you might have an abnormality related to infer-
tility for example, that you can pass on to your children, if you have IVF
treatment. So I almost certainly think that patients will be tested, [and]
if then you find anything [deleterious] then you will be testing the embryo.
Remarkably in this quote, the participant refers to the possibility
‘couples undertaking IVF’ have of being genetically tested before con-
ceiving as a ‘privilege’, in comparison with current PGD couples who
often have to find out about genetic defects the hard way, by having an
affected child first. This participant firmly believes that in the near
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future, all couples visiting the IVF clinic for fertility problems will be
tested for carrying at least the most common genetic diseases.
Should these tests reveal that they are at risk of transferring a
genetic disease, they could then choose to take the PGD route, and
opt for targeted genetic testing, possibly combined with comprehen-
sive chromosome screening. It was objected that with this approach,
potential de novo mutations are not detected. One participant,
however, considered the occurrence of de novo mutations to be too
rare to warrant the use of whole-genome sequencing of the embryo
rather than of the parents:
So in terms of de novo mutations there will be some new mutations that
we will miss. So we will never completely eradicate genetic diseases unless
we do the complete screening of the embryo. But I just think on a practical
level there is so much more to find in the parents than there is in the
embryo.
One uncertainty with regard to preconception testing is whether this
will be provided via the ‘health care system’. Although it was acknowl-
edged that proper genetic counseling is needed both for comprehen-
sive preconception screening and for comprehensive embryo testing,
it was assumed that in the future direct-to-consumer genetic testing
companies may play an important role:
And will happen in the very near future I think is what [. . .] said, will we be
sending our samples to 23andMe for our premarital screening, and we’ll
find out everything and then we will decide . . .
In this quote, she suggests that decisions about which reproductive
route to take may not be made in the context of an official centre
for medical genetics or IVF centre, but may be made by couples be-
forehand, based on the outcome of privately pursued genetic testing.
Our participants suggested that preconception carrier screening
(PCS) ‘may be universally offered’ to couples visiting the IVF clinic.
However, if aneuploidy embryo screening becomes a reliable test,
this could be offered to all IVF couples as well. In the following
quote, one participant argues that the number of potential patients
that may benefit from this technique may increase, and eventually,
the technique may be universally applied in the IVF clinic:
And so I have often argued that if we have a low cost, accurate, compre-
hensive test for errors at the chromosomal level, that was cheap also. . . .
But we don’t have that. If we did have that we’d screen every embryo
before we put it back. Because of the high level of gross genetic abnormal-
ities in embryos . . .
However, another participant stated that comprehensive screening
techniques could be requested by couples that would not be candi-
dates for PGS or PGD at present:
Because exactly what happens in the future, unfortunately I think they are
quite right. It is going to be the wealthy people. . . . I could see a stage
coming where we are really doing this, the rich people decide I want
the healthiest embryo I am going to go to PGD although I am totally
fertile, I am not carrying anything major, but you know we have got
tests for diabetes. . . . That is already there, we could test an embryo on
diabetes predisposition, BRCA and other inherited cancers, so we could
do this now.
In this quote, the participant explicitly worries about the possibility
that affluent couples will want their embryos screened for certain sus-
ceptibility genes, even if they are fertile or not known carriers of
serious diseases. She also states that even at the moment, such
tests could be developed and applied.
When considering the options provided by our participants, it
became clear that genetic testing in the IVF practice may become pri-
marily an issue of ‘smart combinations’. For example, targeted PGD
could be supplemented with comprehensive chromosome screening
to check for the embryo that is free of the disease and has the
most chance of leading to a successful pregnancy. In the context of
PGS, aneuploidy screening could be supplemented with screening
for Mendelian diseases. A recurrent theme in the expert-panel discus-
sion was the idea of offering PCS to all IVF patients prior to treatment.
For example, should PCS of a given couple reveal that this couple is at
risk of transmitting a genetic disease to its offspring, targeted PGD
could be offered. Such targeted PGD could be accompanied by com-
prehensive aneuploidy screening to enhance the chance of a successful
pregnancy. Alternatively, some couples may wish to skip PCS and opt
only for comprehensive embryo screening. In all of these scenarios,
the number of conditions screened for in the tests (both of the
couples as well as the embryos) may vary from a few conditions sim-
ultaneously to the entire genome.
The concept of PCS is not entirely new. It is available mainly in
countries with populations affected by a high frequency of specific re-
cessive diseases, such as the program aimed at detecting carriers of
thalassemia in Cyprus. Now that technologies for widening the
scope of such testing become available, there is a recent trend
toward increasing the number of diseases targeted in preconception
screening, a possibility that is already marketed to the general popula-
tion by some commercial companies (Health Council of the Nether-
lands, 2010; Borry et al., 2011). Our participants saw PCS first and
foremost as a solution to technical problems regarding the interpret-
ation of genetic data. However, it may also serve as a means to
enhance a couple’s reproductive autonomy, as they can now choose
from different reproductive options, such as gamete donation or
adoption, before undertaking burdensome IVF/PGD treatment (De
Wert et al., 2011). Moreover, with comprehensive embryo screening,
the genome of an embryo may be sequenced both as a means to allow
selection and to provide health information about the child to come.
This can have many benefits with regard to prevention and life style
recommendations, but also opens up a whole can of ethical worms
in need of further scrutiny, and the distinction between testing
embryos to make decisions about selection and testing future children
becomes blurred (De Wert, 2009). Indeed, many authors defend that
genetic testing of minors for late onset diseases is in contradiction to
the right of minors (not) to know this information (Borry et al., 2009).
PCS and, if necessary, targeted PGD would avoid the issue of children
being born whose entire genome is known, as a complete scan of the
embryo is not necessary. No doubt PCS also raises its own ethical
issues, such as concerns about possible pressure from healthcare pro-
fessionals, about the further medicalization of procreation and the risk
that public health concerns interfere with reproductive autonomy (De
Wert et al., 2011). Therefore, further reflection on which combination
is the ‘smartest’ from an ethical point of view is also warranted.
Limitations and Conclusion
We acknowledge that our study has several limitations. First, only
PGD scientists and practitioners were part of our expert panel. In
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order to achieve a complete view on the challenges posed by the
introduction of comprehensive screening, other stakeholders such as
IVF and PGD patients, genetic counsellors and fertility doctors
should be interviewed. Also, it may be extremely informative to
compare the views of medical and scientific professionals in this field
with those of sociologists and bioethicists reflecting on these issues.
Secondly, the fact that we had only seven participants from four differ-
ent countries is a severe limitation. However, given the fact that our
participants were pioneers in the field of embryo testing and that to
our knowledge a study of similar design on the topic of comprehensive
embryo testing has not been undertaken before, we believe that this
study has value and can be instructive with regard to possible future
directions of ethical investigation.
In our expert panel, participants agreed that broadening the scope
of embryo testing is a likely development. Such broadening can include
PGD combined with aneuploidy screening, or PGS with testing for
common Mendelian disorders. In the future, it may also include a
whole-genome scan of the embryo. Also, different testing combina-
tions are possible, such as comprehensive PCS followed by targeted
embryo testing and aneuploidy screening, or PCS followed by a whole-
genome sequencing of the embryos. Ethical reflection on this develop-
ment should be both anticipatory and realistic. Indeed, the discourse
regarding the ethical consequences of the genetic revolution has
sometimes focused on futuristic scenarios. Such scenarios include
either selecting the best embryo from widely diverse genetic profiles
or even altering an embryo’s genetic makeup. The possibilities these
developments entail to select against different conditions and aberra-
tions and even character traits have been either hailed or condemned.
At the same time, there is a need for a focus on real-life scenarios
rather than speculations about the future. With the advent of micro-
arrays and whole-genome sequencing in the IVF clinic, the possibility of
considering more comprehensively the genome of preimplantation
embryos is a development going on as we speak. With PGS, this pos-
sibility will not only be limited to couples at high risk of transferring a
genetic condition, but to all IVF patients, and even to all couples with a
desire to have children. However, as our participants have stressed,
selection based on genetic makeup of embryos will, for the time
present, still be severely limited by technical and biological factors.
Moreover, the reflection on the technique of embryo screening itself
should be embedded in a wider reflection on genetic screening at dif-
ferent stages of a subject’s life, as our participants’ emphasis on PCS
has shown.
Our expert panel study has shown that scientists believe an ethical
reflection on the issue, which is both informed by these limitations but
at the same time not afraid of looking ahead, is called for. An uncer-
tainty, which should be further studied, is the extent to which the pos-
sibility to widen selection choices is welcomed or even desired by
infertile coupes seeking IVF or by couples with an indication for
PGD. As Richard Sharp has argued, studying how patients perceive
benefits and risks of multiplexed testing with microarrays may be
the best way to prepare for the more complex issues whole-genome
screening will introduce. Taking small steps may be the best way to
prepare for the huge complexity of data interpretation and counseling
whole-genome screening will entail (Sharp, 2011). We believe that this
holds true also for embryo testing, as microarrays are now gradually
entering the clinical practice.
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